Portal de Periódicos da CAPES

Abemaciclib, a CDK4 and CDK6 Inhibitor for the Treatment of Metastatic Breast Cancer

2020; Future Medicine; Volume: 16; Issue: 33 Linguagem: Inglês

10.2217/fon-2020-0604

1744-8301

Miguel Martín, José A. García‐Sáenz, Luís Manso, Antonio Llombart‐Cussac, Alejo Cassinello, Manuel Atienza, François Ringeisen, Eva Ciruelos,

HER2/EGFR in Cancer Research

The addition of CDK4 and 6 inhibitors (abemaciclib, palbociclib or ribociclib) to endocrine therapy, as first-line treatment or following progression after initial endocrine therapy, significantly increased progression-free survival, objective response rates and in some trials overall survival, compared with endocrine therapy alone in HR+ and HER2- breast metastatic breast cancer. These CDK4 and 6 inhibitors are now approved in this context and have become a new standard of care. A hypothesis-generating exploratory analysis suggested that the addition of abemaciclib to endocrine therapy showed the largest effects in subgroups of women with indicators of poor prognosis, although these data require confirmation. This review provides updated clinical trial data for all three drugs in metastatic breast cancer, focusing on abemaciclib, the most recently approved agent.